|
HY-132161-1mg
|
MedChemexpress LLC
|
MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT [CAS 2378428-19-2]
|
|
Cancer-programmed cell death
|
|
|
HY-132161-5mg
|
MedChemexpress LLC
|
MP-PEG4-Val-Lys-Gly-7-MAD-MDCPT [CAS 2378428-19-2]
|
|
Cancer-programmed cell death
|
|
|
HY-112616-10mg
|
MedChemexpress LLC
|
NAMPT inhibitor-linker 2 [CAS 2241014-82-2]
|
|
Cancer-programmed cell death
|
|
|
HY-112616-100mg
|
MedChemexpress LLC
|
NAMPT inhibitor-linker 2 [CAS 2241014-82-2]
|
|
Cancer-programmed cell death
|
|
|
HY-112616-25mg
|
MedChemexpress LLC
|
NAMPT inhibitor-linker 2 [CAS 2241014-82-2]
|
|
Cancer-programmed cell death
|
|
|
HY-112616-5mg
|
MedChemexpress LLC
|
NAMPT inhibitor-linker 2 [CAS 2241014-82-2]
|
|
Cancer-programmed cell death
|
|
|
HY-112616-50mg
|
MedChemexpress LLC
|
NAMPT inhibitor-linker 2 [CAS 2241014-82-2]
|
|
Cancer-programmed cell death
|
|
|
HY-108831A-1mg
|
MedChemexpress LLC
|
Natalizumab (Solution) [CAS 189261-10-7]
|
|
|
|
|
HY-108831A-10mg
|
MedChemexpress LLC
|
Natalizumab (Solution) [CAS 189261-10-7]
|
|
|
|
|
HY-108831A-25mg
|
MedChemexpress LLC
|
Natalizumab (Solution) [CAS 189261-10-7]
|
|
|
|
|
HY-108831A-5mg
|
MedChemexpress LLC
|
Natalizumab (Solution) [CAS 189261-10-7]
|
|
|
|
|
HY-108831-10mg
|
MedChemexpress LLC
|
Natalizumab [CAS 189261-10-7]
|
|
COVID-19-immunoregulation
|
|
|
HY-108831-25mg
|
MedChemexpress LLC
|
Natalizumab [CAS 189261-10-7]
|
|
COVID-19-immunoregulation
|
|
|
HY-108831-5mg
|
MedChemexpress LLC
|
Natalizumab [CAS 189261-10-7]
|
|
COVID-19-immunoregulation
|
|
|
HY-P99750-1mg
|
MedChemexpress LLC
|
Navivumab [CAS 1443004-16-7]
|
|
|
|
|
HY-P99750-10mg
|
MedChemexpress LLC
|
Navivumab [CAS 1443004-16-7]
|
|
|
|
|
HY-P99750-5mg
|
MedChemexpress LLC
|
Navivumab [CAS 1443004-16-7]
|
|
|
|
|
HY-W046471-100mg
|
MedChemexpress LLC
|
N-Boc-PEG4-bromide [CAS 1076199-21-7]
|
|
Cancer-programmed cell death
|
|
|
HY-W046471-250mg
|
MedChemexpress LLC
|
N-Boc-PEG4-bromide [CAS 1076199-21-7]
|
|
Cancer-programmed cell death
|
|
|
HY-W046471-500mg
|
MedChemexpress LLC
|
N-Boc-PEG4-bromide [CAS 1076199-21-7]
|
|
Cancer-programmed cell death
|
|
|
HY-148819A-1mg
|
MedChemexpress LLC
|
NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT (hydrochloride)
|
|
|
|
|
HY-148819A-10mg
|
MedChemexpress LLC
|
NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT (hydrochloride)
|
|
|
|
|
HY-148819A-25mg
|
MedChemexpress LLC
|
NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT (hydrochloride)
|
|
|
|
|
HY-148819A-5mg
|
MedChemexpress LLC
|
NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT (hydrochloride)
|
|
|
|
|
HY-W002213-500mg
|
MedChemexpress LLC
|
N-Hydroxysulfosuccinimide (sodium) [CAS 106627-54-7]
|
|
Cancer-programmed cell death
|
|
